Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the Extraordinary General Meeting on 24.04.2023 (the “EGM”) that will take place at the offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp. The meeting will start at 14:00 hours CEST and is to be attended physically. Registration will start at 13:00 hours CEST.
Hoofddorp, the Netherlands, 08 December 2022. IGEA Pharma N.V. (SIX: IGPH) today appointed Diego Fiorentini as new CFO of IGEA Pharma, filling a void that was ad interim covered by the previous CEO.
Minutes of the Annual General Meeting (the ‘Meeting‘) of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands), and address at: (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821 (the ‘Company‘), held via (i) Zoom and (ii) in the meeting room next to the Company’s office with address at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 1 December 2022 at 11.00 hours CEST.
Hoofddorp, the Netherlands, 06 December 2022. IGEA Pharma N.V. (SIX: IGPH) today announced that the Annual General Meeting approved all the agenda resolutions. The minutes of the meeting are available at igeapharma.nl/category/information-for-shareholders
Hoofddorp, the Netherlands, 30 October 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its Half-2022 Financial Report.
Documents for download:
Hoofddorp, the Netherlands, 20 October 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its 2021 Annual Report.
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites the shareholders to attend the annual general meeting on 1 December 2022 (the “AGM”), at the offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands. The meeting will start at 11:00 hours CET. Registration will start at 10:30 hours CET.
Hoofddorp, the Netherlands, 30 September 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the half year 2022 report.